Back to top
more

DaVita (DVA)

(Delayed Data from NYSE)

$127.69 USD

127.69
1,118,217

-0.12 (-0.09%)

Updated Aug 7, 2025 04:00 PM ET

After-Market: $127.70 +0.01 (0.01%) 7:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 27% (66 out of 246)

Industry: Medical - Outpatient and Home Healthcare

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Founded in 1994 and headquartered in Denver, CO, DaVita Inc. is a leading provider of dialysis services in the U.S. to patients suffering from chronic kidney failure, also known as end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related medical services primarily in dialysis centers and in contracted hospitals across the U.S. Its services include outpatient dialysis services, hospital inpatient dialysis services and ancillary services such as ESRD laboratory services and disease management services.

Zacks Equity Research

Masimo (MASI) Preliminary Q2 Results Aided by Healthcare Unit

by Zacks Equity Research

Masimo's (MASI) second-quarter 2024 results are likely to reflect the strength in the Healthcare business.

Zacks Equity Research

Inspire Medical (INSP) Dips on FDA Recall of IPG Model 3028

by Zacks Equity Research

The recall of Inspire Medical 's (INSP) Inspire IV Implantable Pulse Generators might dampen the company's future sales.

Zacks Equity Research

Here's Why DaVita HealthCare (DVA) is a Strong Value Stock

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Equity Research

DaVita HealthCare (DVA) Surpasses Market Returns: Some Facts Worth Knowing

by Zacks Equity Research

DaVita HealthCare (DVA) concluded the recent trading session at $137.92, signifying a +0.39% move from its prior day's close.

Zacks Equity Research

Olink's (OLK) Acquisition by Thermo Fisher Gets UK CMA Nod

by Zacks Equity Research

Olink's (OLK) buyout by Thermo Fisher gets CMA's approval, signaling regulatory confidence in the merger's compliance with competition laws.

Zacks Equity Research

Stryker (SYK) Gains 11.6% YTD: What's Driving the Stock?

by Zacks Equity Research

Styker's (SYK) flagship Mako Total Knee Platform and a diversified product portfolio raise optimism about the stock.

Zacks Equity Research

Baxter (BAX) Recovers After Life2000 Ventilation Systems Recall

by Zacks Equity Research

Baxter (BAX) recalls Life2000 ventilators due to damaged battery charger dongles, posing a risk of device failure

Zacks Equity Research

Smith & Nephew's (SNN) 5% Stake Acquired by Cevian Capital

by Zacks Equity Research

Smith & Nephew (SNN) eyes future growth as Cevian Capital purchases a 5% stake in the company.

Zacks Equity Research

Three Reasons to Hold BD (BDX) Stock in Your Portfolio Now

by Zacks Equity Research

BD's (BDX) robust product portfolio raises optimism about the stock.

Zacks Equity Research

Masimo (MASI) Fights Politan in a Bid to Retain CEO on Board

by Zacks Equity Research

Will Masimo (MASI) lose its CEO in its fight against activist investor Politan Capital Management? The company's management and employees want Joe Kiani to continue as the CEO.

Zacks Equity Research

DexCom (DXCM), Abbott to Launch First FDA Cleared OTC CGMs

by Zacks Equity Research

Dexcom (DXCM) and Abbott are set to launch their first FDA-approved over-the-counter CGMs, Stelo and Lingo & Libre Rio, respectively, in the United States this summer.

Zacks Equity Research

Microbot Medical (MBOT) Inks Agreement to Begin LIBERTY Trial

by Zacks Equity Research

Microbot Medical's (MBOT) LIBERTY Endovascular Robotic System trial expands to Baptist Hospital of Miami, promising advancements in clinical outcomes and endovascular procedures.

Zacks Equity Research

Cardinal Health (CAH) Recalls Kits Containing Shenli's Syringes

by Zacks Equity Research

Cardinal Health (CAH) recalls its procedure kits that contain plastic syringes manufactured by a Chinese manufacturer, Jiangsu Shenli.

Zacks Equity Research

Lucid Diagnostics (LUCD) Reports Positive ESOGUARD BE-1 Data

by Zacks Equity Research

Lucid Diagnostic's (LUCD) ESOGUARD BE-1 study data shows high sensitivity and negative predictive value for the EsoGuard test, enhancing early detection of esophageal precancer in a screening population.

Zacks Equity Research

Here's Why You Should Add DaVita (DVA) to Your Portfolio Now

by Zacks Equity Research

DaVita's (DVA) strength in its kidney care segment raises optimism about the stock.

Zacks Equity Research

KORU Medical's (KRMD) FreedomEdge Gets Regulatory Nod in Japan

by Zacks Equity Research

KORU Medical (KRMD) announces the receipt of regulatory clearance for its FreedomEdge System in Japan.

Zacks Equity Research

Merit Medical (MMSI) Inks Deal to Boost Endoscopy Portfolio

by Zacks Equity Research

Merit Medical's (MMSI) latest asset acquisition is likely to expand its endoscopy portfolio with a minimally-invasive solution for GERD patients, thereby improving patient outcomes.

Zacks Equity Research

IceCure Medical (ICCM) New Cryoablation System Gets FDA Nod

by Zacks Equity Research

IceCure Medical's (ICCM) XSense Cryoablation System receives FDA approval, marking a pivotal step in minimally-invasive tumor treatment across multiple medical fields

Zacks Equity Research

Reasons to Retain Revvity (RVTY) Stock in Your Portfolio Now

by Zacks Equity Research

Revvity's (RVTY) strong product portfolio raises optimism about the stock.

Zacks Equity Research

Here's Why You Should Retain Glaukos (GKOS) Stock for Now

by Zacks Equity Research

Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.

Zacks Equity Research

Avantor (AVTR) Launches Solutions for Gene Therapy Harvest

by Zacks Equity Research

Avantor's (AVTR) solutions are intended to provide gene therapy manufacturers with sustainable and efficient alternatives to traditional methods, thus improving viral particle harvest and quality

Zacks Equity Research

Masimo's (MASI) WI Sport Wearable Gets a New Powerful Feature

by Zacks Equity Research

Masimo (MASI) announces Sleep Halo, a new feature for its Masimo W1 Sport advanced health tracking wearable.

Zacks Equity Research

GE Healthcare (GEHC) Enters Partnership to Boost MRI Technology

by Zacks Equity Research

GE Healthcare's (GEHC) alliance is likely to establish an Innovative MRI Research and Development center to advance MRI innovation and patient care

Zacks Equity Research

Reasons to Retain PacBio (PACB) Stock in Your Portfolio Now

by Zacks Equity Research

PacBio's (PACB) strong product demand and continued focus on R&D raise optimism about the stock.

Zacks Equity Research

Tandem Diabetes (TNDM) Posts Positive Data for Tandem Mobi

by Zacks Equity Research

Tandem Diabetes (TNDM) unveils survey results of the new Tandem Mobi insulin delivery system, underscoring its potential to significantly enhance the quality of life for people with diabetes